To include your compound in the COVID-19 Resource Center, submit it here.

Astellas' peficitinib meets in Phase III for RA

Astellas Pharma Inc. (Tokyo:4503) reported top-line data from the Phase III RAJ3 trial in about 500 patients with rheumatoid arthritis who had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs)

Read the full 301 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE